Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations

Basit Öğe Kaydı
dc.contributor.authorCasal Moura, Marta
dc.contributor.authorGauckler, Philipp
dc.contributor.authorAnders, Hans-Joachim
dc.contributor.authorBruchfeld, Annette
dc.contributor.authorFernandez-Juarez, Gema M.
dc.contributor.authorFloege, Juergen
dc.contributor.authorFrangou, Eleni
dc.date.accessioned2024-02-23T14:21:02Z
dc.date.available2024-02-23T14:21:02Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractUpdated guidelines on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were released in 2021 by the American College of Rheumatology jointly with the Vasculitis Foundation and, subsequently, in 2022 by the European Alliance of Associations for Rheumatology. In addition, in 2021, the Kidney Disease: Improving Global Outcomes had released updated recommendations on the treatment of AAV with glomerulonephritis (AAV-GN). Kidney involvement is particularly relevant in microscopic polyangiitis and granulomatosis with polyangiitis, but is less frequent in eosinophilic granulomatosis with polyangiitis. The management of AAV-GN has been a focus for drug development and change over the past 10 years. Avoidance of progression to end-stage kidney disease (ESKD) or kidney failure is one of the main unmet needs in the management of AAV, with ESKD having a major impact on morbidity, health costs and mortality risk. Relevant changes in AAV-GN management are related to remission-induction treatment of patients with severe kidney disease, the use of glucocorticoids and avacopan, and remission-maintenance treatment. All the documents provide guidance in accordance with the evidence-based standard of care available at the time of their release. With our work we aim to (i) show the progress made and identify the differences between guidelines and recommendations, (ii) discuss the supporting rationale for those, and (iii) identify gaps in knowledge that could benefit from additional research and should be revised in subsequent updates.en_US
dc.identifier.doi10.1093/ndt/gfad090
dc.identifier.endpage2651en_US
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issue11en_US
dc.identifier.pmid37164940en_US
dc.identifier.scopus2-s2.0-85171743428en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2637en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfad090
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13421
dc.identifier.volume38en_US
dc.identifier.wosWOS:001013918500001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnca-Associated Vasculitisen_US
dc.subjectGlomerulonephritisen_US
dc.subjectGranulomatosis With Polyangiitisen_US
dc.subjectGuidelinesen_US
dc.subjectMicroscopic Polyangiitisen_US
dc.titleManagement of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendationsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu